TrialJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2025

LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy.

Natasha B Leighl et al.PubMed ↗Publisher ↗

No numbers read from the abstract.